Apimeds Pharmaceuticals US, Inc. (APUS): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$8.98M

Year ended 2025-12-31

-$13.33M

Trailing 12 months to 2026-06-30

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$8.98M	n/a	2026-05-04, From 2025-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Apimeds Pharmaceuticals US, Inc. (APUS)	2025-12-31	-$8.98M	n/a
Transcode Therapeutics, Inc. (RNAZ)	2025-12-31	-$19.52M	n/m
Gyre Therapeutics, Inc. (GYRE)	2025-12-31	-$180.0K	n/m
Climb Bio, Inc. (CLYM)	2025-12-31	-$54.54M	n/m
Aclaris Therapeutics, Inc. (ACRS)	2025-12-31	-$47.22M	n/m
Aquestive Therapeutics, Inc. (AQST)	2025-12-31	-$52.99M	n/m
Corbus Pharmaceuticals Holdings, Inc. (CRBP)	2025-12-31	-$64.50M	n/m
Boundless Bio, Inc. (BOLD)	2025-12-31	-$47.21M	n/m
Gossamer Bio, Inc. (GOSS)	2025-12-31	-$171.34M	n/m

Compare APUS, RNAZ, GYRE, CLYM side by side · Screen every company in Pharmaceutical Preparations ↗